Siemens Medical Solutions is poised to enter the prone stereotactic breast biopsy market later this year, as the result of a consent agreement signed last week by Hologic and the Federal Trade Commission regarding assets Hologic purchased last year from Fischer Imaging (DI SCAN 7/10/06, FTC scuttles Hologic purchase of some Fischer Imaging assets).
Siemens Medical Solutions is poised to enter the prone stereotactic breast biopsy market later this year, as the result of a consent agreement signed last week by Hologic and the Federal Trade Commission regarding assets Hologic purchased last year from Fischer Imaging (DI SCAN 7/10/06, FTC scuttles Hologic purchase of some Fischer Imaging assets).
Confidentiality agreements govern disclosures regarding the agreement involving Fischer's MammoTest prone biopsy assets. As a result, some details are unknown, including how Siemens ultimately landed these assets. Interviews between DI SCAN and FTC staff attorneys, however, illuminate much of the process.
Tammy Imhoff, a staff attorney in the FTC Bureau of Competition involved in the Hologic/Fischer case, stated emphatically that the commission did not pick Siemens, but rather reviewed - favorably - Hologic/Fischer's choice of the company.
"We don't want to become a deal broker and tell parties who they have to divest assets to," Imhoff said. "Our view is that they have to meet our criteria, and that includes having a package of assets that is sufficient and can be an independent and strong competitor."
Siemens meets these requirements as they relate to the Fischer prone biopsy assets.
"We feel very strongly that, with these assets, Siemens can be every bit as competitive as Fischer was before the acquisition," said Jeffrey H. Perry, another FTC Bureau of Competition staff attorney involved in the case. "The company is on a tier that not many other companies share in terms of its ability to compete in these diagnostic imaging markets and even in the narrower field of breast imaging and breast biopsy. We think it is an ideal solution with an ideal buyer for the assets."
As part of the consent agreement, Hologic has agreed to sell all of the intellectual property relating to the Fischer MammoTest system to Siemens AG for a cash payment of $6.5 million. This agreement was achieved as part of a method known as buyer up-front.
Perry explained that this method identifies the assets that must be sold, as well as the buyer of those assets, before the FTC order is accepted. Alternatively, the FTC may simply identify the package of assets that must be divested and leave identification of the buyer until after the commission's order is accepted. The latter approach, known as a post-order divestiture, is typically used when the assets being divested constitute a stand-alone business. That is not the situation with Hologic and Fischer, which had been (and in the case of Hologic continues to be) involved in various aspects of mammography and x-ray imaging.
In either case, however, the FTC conducts a two-part analysis:
The FTC necessarily gets involved early in the "buyer up-front" divestiture, but the commission's analysis is exactly the same in both cases, according to Perry. The FTC also strives not to penalize the company ordered to divest assets.
In Hologic's case this means that it will retain a "royalty-free, nonexclusive, perpetual, irrevocable, worldwide right and license to use the intellectual property relating to the MammoTest system," according to the company.
Mammography News: FDA Grants Expanded 510(k) Clearance for AI-Powered SmartMammo Dx DBT Software
November 29th 2024Originally cleared by the FDA in 2021, the SmartMammo Dx software for digital breast tomosynthesis (DBT) can now be utilized with the Senographe Pristina mammography systems from GE HealthCare.
Is the Kaiser Score More Effective than BI-RADS for Assessing Contrast-Enhanced Mammography and MRI?
October 14th 2024For women with breast-enhanced masses, Kaiser scoring (KS) demonstrated a 20 percent higher AUC than BI-RADS classification for contrast-enhanced mammography (CEM) and was comparable to KS for breast MRI.